
|Articles|August 1, 2004
Aldara gets FDA nod for treatment of sBCC
St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Harrison Nguyen, MD, MBA, MPH’s Deep Dive into CSU, Vasculitis, and Autoimmune Blisters
2
Day 3 Recap: SDPA Fall 2025
3
From TikTok to Targeted Therapy: Shannon Trotter, DO, on Modern Dermatology Challenges
4
Q&A: Why Oncologist-Dermatologist Collaboration is Essential for Managing Systemic Mastocytosis
5



















